Alfred Sandrock

Alfred W Sandrock joined the Neurimmune Board of Directors in 2022. Al is recognized as an outstanding industry leader who brought numerous transformational therapies for the treatment of neurological diseases to patients. He spearheaded the development of Tysabri®, Tecfidera®, Spinraza®, Plegridy®, and most recently AduhelmTM. In his 23-year career at Biogen, Al served in various functions including as an Executive Committee Member, Head of Research & Development and Chief Medical Officer. He holds an MD degree from Harvard Medical School and a PhD degree from Harvard University.